Hydromer, Inc., a leader in medical device coating technology, has reported a 9% decline in revenue for the first quarter of 2025 compared to the same period in the previous year. The company's preliminary unaudited financial results showed quarterly revenue of $1.0 million, down from $1.1 million in Q1 2024. Net income also saw a significant decrease, falling 64% to $112,000. CEO Michael Torti pointed to legacy customer attrition and the typical onboarding delays in the medical coatings sector as primary reasons for the downturn.
Despite these financial setbacks, Hydromer is not deterred from its strategic path. The company has continued to invest in product development and commercial infrastructure, aiming to enhance its product pipeline and penetrate higher-value markets. This approach underscores Hydromer's commitment to long-term growth and innovation in the medical coatings industry.
In addition to focusing on product and market development, Hydromer has been working on improving its financial record-keeping under new management. However, the company has decided to delay a comprehensive U.S. GAAP audit, prioritizing current cash resources for operational and strategic initiatives.
As an ISO 9001:2015 certified global provider of surface modification and coating solutions, Hydromer serves a diverse clientele across the United States, Europe, and Asia-Pacific. The company prides itself on maintaining compliance with FDA, GMP, ISO 13485, and ISO 9001 standards, alongside developing proprietary coating formulations over its 40-year history. Hydromer's strategy emphasizes operational efficiency, strengthening customer partnerships, and advancing next-generation technology to secure its position in the competitive medical device coating market.
